Promising Results from the FRONTIER 5 Study Recent data published regarding Novo Nordisk’s investigative therapy, denecimig, has provided a hopeful update for the haemophilia community. The Phase 1/2a FRONTIER 5 clinical trial specifically evaluated the safety and tolerability of switching patients from emicizumab to denecimig. Key Findings on Tolerability The study focused on whether patients…

Advancements in Haemophilia A Research A recent clinical study has provided encouraging data for individuals living with Haemophilia A. The FRONTIER5 study evaluated the use of denecimig, an investigational therapy, specifically focusing on patients transitioning from emicizumab. Key Findings from the FRONTIER5 Study The primary focus of this clinical trial was to assess the safety…